AR128043A1 - Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación - Google Patents
Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparaciónInfo
- Publication number
- AR128043A1 AR128043A1 ARP220103523A ARP220103523A AR128043A1 AR 128043 A1 AR128043 A1 AR 128043A1 AR P220103523 A ARP220103523 A AR P220103523A AR P220103523 A ARP220103523 A AR P220103523A AR 128043 A1 AR128043 A1 AR 128043A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- salt
- formula
- salts
- solid form
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 title abstract 2
- 150000003839 salts Chemical group 0.000 abstract 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- ZBHJWDKPRTVNKG-VQTJNVASSA-N CC1=C(C=CC=C1C)C1=C(C=C2C(=N1)C(=NN2)C=1C=CC(=NC=1)N1C[C@H]2N(CC1)C[C@@H](C2)O)OC Chemical compound CC1=C(C=CC=C1C)C1=C(C=C2C(=N1)C(=NN2)C=1C=CC(=NC=1)N1C[C@H]2N(CC1)C[C@@H](C2)O)OC ZBHJWDKPRTVNKG-VQTJNVASSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000001361 adipic acid Substances 0.000 abstract 1
- 235000011037 adipic acid Nutrition 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a sales y formas sólidas del inhibidor de FGFR (7R,8aS)-2-(5-(5-(2,3-dimetilfenil)-6-metoxi-1H-pirazolo[4,3-b]piridin-3-il)piridin-2-il)octahidropirrolo[1,2-a]pirazin-7-ol, e incluye métodos para su preparación, en donde los compuestos, las sales y las formas sólidas son útiles en el tratamiento de enfermedades mediadas por FGFR, tales como el cáncer. Reivindicación 1: Una forma sólida del Compuesto 1 con la fórmula: (1), caracterizada porque la forma sólida es cristalina. Reivindicación 17: Una sal caracterizada porque es una sal de adición de ácido del Compuesto 1, que tiene la estructura: de fórmula (1), en donde el ácido es ácido fosfórico, ácido clorhídrico, ácido L-tartárico, ácido malónico, ácido metanosulfónico, ácido adípico, ácido fumárico, ácido maleico, ácido málico o ácido succínico. Reivindicación 82: Un proceso para preparar el Compuesto 1 con la fórmula: (1), o una sal de este, caracterizado porque comprende: desproteger el Compuesto 2 con la fórmula: (2), o una sal de este, con A1, en donde A1 es un ácido. Reivindicación 117: Una composición farmacéutica caracterizada porque comprende una forma sólida de cualquiera de las reivindicaciones 1 - 16, o una sal de cualquiera de las reivindicaciones 17 - 81, y un portador o excipiente farmacéuticamente aceptable. Reivindicación 118: Un método para inhibir una enzima FGFR3, caracterizado porque comprende poner en contacto una forma sólida de cualquiera de las reivindicaciones 1 - 16 o una sal de cualquiera de las reivindicaciones 17 - 81 con dicha enzima.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292628P | 2021-12-22 | 2021-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128043A1 true AR128043A1 (es) | 2024-03-20 |
Family
ID=85172903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103523A AR128043A1 (es) | 2021-12-22 | 2022-12-21 | Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230192722A1 (es) |
| EP (1) | EP4452982A1 (es) |
| JP (1) | JP2025500466A (es) |
| KR (1) | KR20240136984A (es) |
| CN (1) | CN118660889A (es) |
| AR (1) | AR128043A1 (es) |
| AU (1) | AU2022418585A1 (es) |
| CA (1) | CA3244187A1 (es) |
| CL (1) | CL2024001873A1 (es) |
| CO (1) | CO2024009568A2 (es) |
| CR (1) | CR20240297A (es) |
| IL (1) | IL313735A (es) |
| MX (1) | MX2024007951A (es) |
| PE (1) | PE20250776A1 (es) |
| TW (1) | TW202340215A (es) |
| WO (1) | WO2023122134A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103429243B (zh) | 2010-10-25 | 2016-06-08 | G1治疗公司 | Cdk抑制剂 |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102685249B1 (ko) | 2016-06-20 | 2024-07-17 | 인사이트 코포레이션 | 면역조절제로서의 복소환식 화합물 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3047991A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119224A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| MD3790877T2 (ro) | 2018-05-11 | 2023-08-31 | Incyte Corp | Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1 |
| TWI891666B (zh) * | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
-
2022
- 2022-12-21 AR ARP220103523A patent/AR128043A1/es unknown
- 2022-12-21 CA CA3244187A patent/CA3244187A1/en active Pending
- 2022-12-21 EP EP22854263.5A patent/EP4452982A1/en not_active Withdrawn
- 2022-12-21 WO PCT/US2022/053582 patent/WO2023122134A1/en not_active Ceased
- 2022-12-21 KR KR1020247024528A patent/KR20240136984A/ko active Pending
- 2022-12-21 IL IL313735A patent/IL313735A/en unknown
- 2022-12-21 CN CN202280091209.6A patent/CN118660889A/zh active Pending
- 2022-12-21 PE PE2024001456A patent/PE20250776A1/es unknown
- 2022-12-21 MX MX2024007951A patent/MX2024007951A/es unknown
- 2022-12-21 US US18/085,814 patent/US20230192722A1/en active Pending
- 2022-12-21 TW TW111149106A patent/TW202340215A/zh unknown
- 2022-12-21 AU AU2022418585A patent/AU2022418585A1/en active Pending
- 2022-12-21 CR CR20240297A patent/CR20240297A/es unknown
- 2022-12-21 JP JP2024538174A patent/JP2025500466A/ja active Pending
-
2024
- 2024-06-19 CL CL2024001873A patent/CL2024001873A1/es unknown
- 2024-07-19 CO CONC2024/0009568A patent/CO2024009568A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240297A (es) | 2024-09-18 |
| MX2024007951A (es) | 2024-07-10 |
| WO2023122134A1 (en) | 2023-06-29 |
| US20230192722A1 (en) | 2023-06-22 |
| JP2025500466A (ja) | 2025-01-09 |
| AU2022418585A1 (en) | 2024-07-11 |
| CO2024009568A2 (es) | 2024-07-29 |
| CL2024001873A1 (es) | 2024-12-06 |
| TW202340215A (zh) | 2023-10-16 |
| CA3244187A1 (en) | 2023-06-29 |
| IL313735A (en) | 2024-08-01 |
| PE20250776A1 (es) | 2025-03-14 |
| CN118660889A (zh) | 2024-09-17 |
| KR20240136984A (ko) | 2024-09-19 |
| EP4452982A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| AU2024266792A1 (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor | |
| PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| PE20250776A1 (es) | Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion | |
| BR112023005320A2 (pt) | Forma a polimórfica cristalina do composto 1 ((r)-4-((1-(2-cianoacetil)piperidin-3-il)amino)-1h-pirrolo[2,3-b] piridina-5-carboxilato de etil), método para preparar a forma a polimórfica cristalina do composto 1((r)-4-((1-(2-cianoacetil)piperidin-3-il)amino)-1h -pirrolo[2,3-b]piridina-5-carboxilato de etil) e processo para preparar o composto 1 | |
| EA201400701A1 (ru) | Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk) | |
| NZ605627A (en) | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase | |
| MX2020002711A (es) | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. | |
| MX2015001023A (es) | Proceso para preparacion de derivados de acido pirazol carboxilico. | |
| PE20120629A1 (es) | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina | |
| ME01999B (me) | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b | |
| BR122020005540B8 (pt) | processos para preparar composições de inibidores jak | |
| MX2016015874A (es) | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
| TW201004953A (en) | Substituted alkyl pyrimidin-4-one derivatives | |
| PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| CY1122514T1 (el) | Σουλφονικος υδροξυαιθυλεστερας του αναστολεα της εξαρτωμενης απο κυκλινη πρωτεϊνικης κινασης, κρυσταλλικη μορφη αυτου και μεθοδος παρασκευης αυτου | |
| CL2023000992A1 (es) | Procedimiento para racemizar y aislar atropisómeros de 7-cloro-6-fluoro-1-(2-isopropil-4-metilpiridin-3-il)pirido[2,3-d]pirimidin-2,4(1h,3h)-diona | |
| CL2025000236A1 (es) | Sal del compuesto imidazo[1,2-a]piridina, forma cristalina de la misma y método de preparación. | |
| PE20142244A1 (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina | |
| BR112021024533A2 (pt) | Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo | |
| AR126101A1 (es) | Heterociclos tricíclicos como inhibidores de fgfr | |
| AR085291A1 (es) | Metodos para sintetizar derivados del precursor z de molibdopterina | |
| AR125144A1 (es) | Nuevo proceso | |
| EA202190643A1 (ru) | УЛУЧШЕННЫЙ СПОСОБ ПРОИЗВОДСТВА 3-[(1S)-1-ИМИДАЗО[1,2-a]ПИРИДИН-6-ИЛЭТИЛ]-5-(1-МЕТИЛПИРАЗОЛ-4-ИЛ)ТРИАЗОЛО[4,5-b]ПИРАЗИНА И ЕГО ПОЛИМОРФНЫХ ФОРМ | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. |